INT346565

From wiki-pain
Revision as of 10:11, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2010
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 1
Total Number 13
Disease Relevance 2.93
Pain Relevance 0.42

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Sh3gl3) endosome (Sh3gl3) cytoplasm (Sh3gl3)
Anatomy Link Frequency
urine 3
visceral 2
DRG 1
kidney 1
Sh3gl3 (Mus musculus)
Pain Link Frequency Relevance Heat
Neuropathic pain 26 98.80 Very High Very High Very High
Peripheral nervous system 26 94.24 High High
hypoalgesia 13 82.40 Quite High
peripheral neuropathy 39 79.04 Quite High
Spinal cord 26 5.00 Very Low Very Low Very Low
anesthesia 13 5.00 Very Low Very Low Very Low
analgesia 13 5.00 Very Low Very Low Very Low
isoflurane 13 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Fabry Disease 234 99.44 Very High Very High Very High
Neuropathic Pain 39 98.80 Very High Very High Very High
Disease 143 98.04 Very High Very High Very High
Gauchers Disease 91 96.00 Very High Very High Very High
Disease Progression 26 95.80 Very High Very High Very High
Renal Failure 13 94.44 High High
Heart Disease 13 93.60 High High
Renal Insufficiency 13 87.52 High High
Hypoalagesia 13 82.40 Quite High
Cerebrovascular Disease 26 81.16 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The neuropathic pain characteristic of Fabry disease may have its origin in the accumulation of GL-3 in DRG neurons and their subsequent destruction [33].
Positive_regulation (accumulation) of GL-3 in DRG associated with neuropathic pain and fabry disease
1) Confidence 0.26 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.20 Pain Relevance 0.14
Consistent with this view, a screening of renal parameters in our mouse model revealed increases in urine volume and urine GL-3 that could be used as biomarkers related to the disease process.
Positive_regulation (increases) of GL-3 in urine associated with disease
2) Confidence 0.23 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.76 Pain Relevance 0
-gal is unable to remove GL-3 from all tissues to the same degree.
Neg (unable) Positive_regulation (remove) of GL-3
3) Confidence 0.19 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.23 Pain Relevance 0.17
Treated Fabry mice also continued to accumulate GL-3 throughout the course of the study, but did so at a reduced rate, generally resulting in significant net GL-3 reductions of 40–50% by the end of the study.
Positive_regulation (accumulate) of GL-3
4) Confidence 0.19 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0 Pain Relevance 0
Collectively, these results in the Fabry mouse suggest that SRT with eliglustat tartrate can provide benefit by delaying GL-3 accumulation and its attendant (renal and neurologic) symptoms.
Positive_regulation (accumulation) of GL-3
5) Confidence 0.18 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.20 Pain Relevance 0.08
Also, the degree of accumulated GL-3 clearance varies depending upon the cell-type [8].
Positive_regulation (accumulated) of GL-3
6) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.60 Pain Relevance 0
SRT reduces the rate of GL-3 accumulation in visceral tissues
Positive_regulation (accumulation) of GL-3 in visceral
7) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.06 Pain Relevance 0
Although multiple symptoms are apparent in patients, Fabry mouse models are relatively normal except for modest accumulation of GL-3.
Neg (except) Positive_regulation (accumulation) of GL-3
8) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.25 Pain Relevance 0.03
The kidney and urine both showed highly significant improvements in GL-3 levels with either regimen of combination therapy (ERT2 or ERT4) when compared to the ERT alone group.
Positive_regulation (improvements) of GL-3 in urine
9) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0 Pain Relevance 0
Figure 1 shows that in untreated mice, all the visceral tissues evaluated (liver, kidney, heart and spleen) as well as whole blood, accumulated GL-3 over the 11 month course of the study to levels at least 100-fold higher than wild-type control GL-3 levels.
Positive_regulation (accumulated) of GL-3 in visceral
10) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0 Pain Relevance 0
Figure 2C depicts the total GL-3 excreted over 24 h, showing that although SRT significantly decreased urine GL-3 (?
Positive_regulation (urine) of GL-3 in urine
11) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.12 Pain Relevance 0
Here, we show that such an inhibitor (eliglustat tartrate, Genz-112638) was effective at lowering GL-3 accumulation in a mouse model of Fabry disease.
Positive_regulation (accumulation) of GL-3 associated with fabry disease
12) Confidence 0.15 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2991350 Disease Relevance 0.52 Pain Relevance 0
The kidney and urine both showed highly significant improvements in GL-3 levels with either regimen of combination therapy (ERT2 or ERT4) when compared to the ERT alone group.
Positive_regulation (improvements) of GL-3 in kidney
13) Confidence 0.06 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox